On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

International Stem Cell Corp. (ISCOD) Prepares To Up-List, Tightens Share Structure Ahead of Landmark Parkinson’s Clinical Trial

With the success of its nine-month GLP safety (tumorigenicity) and biodistribution animal model study in Parkinson’s Disease (PD) showing a completely clean record, as zero tumor growth was observed across a batch of 300 rodents injected with the company’s ethically and proprietarily-derived human neural stem cells (hpNSCs), International Stem Cell Corp. has subsequently taken a major step to increase the company’s market presence and up-list to a major exchange, announcing a reverse stock split in order to tighten the overall share structure. Since the July 29 split announcement, the company’s ticker has been ISCOD, and it will remain so until the typical period of approximately 20 days has elapsed.

The recently completed nine month GLP safety study, which capitalizes on a long track record of successfully demonstrated results stretching back to such examples as the 2013 work with Duke University’s Clinical Research Institute, was the last step needed for International Stem Cell to secure the previously announced landmark phase 1/2a clinical trial in PD with the Australian Therapeutic Goods Administration via the company’s recently-formed Australian subsidiary, Cyto Therapeutics Pty Ltd. The company has quite a preclinical dataset to back up its novel approach to treating PD with injected hpNSCs, which are self-renewing multipotent precursor cells to the main types of cells that make up the CNS (central nervous system), created using the company’s proprietary parthenogenetic technology, which chemically differentiates unfertilized human eggs (oocytes) into pluripotent stem cells (capable of giving rise to many different cell types).

This extensive preclinical dataset the company has thus far amassed, showing zero evidence of tumor formation at even high dosages (including proof-of-principle PD cohort studies and additional studies focused on safety), combined with direct evidence that injected hpNSCs exhibit a neuroprotectant capacity, as well as an ability to actively recover neurons and address the core motor function symptomatology of PD characterized by dopamine deficiency, is an extremely positive forward indicator to investors. International Stem Cell Corporation has been steamrollering forward with incredible momentum in 2015, ever since the announcement in December of last year that the EU’s Court of Justice ruled in favor of the company’s core technology patent applications, declaring them to be effectively outside the scope of prohibitions on patenting embryonic stem cells, due to a laser-like focus on only ethical derivation of non-embryonic stem cells from unfertilized eggs. Ethically-derived sourcing is a key advantage for International Stem Cell Corporation, especially in the current environment, where a political and ethical debate about stem cell technology is heating up.

Highlights for the company so far this year include solid Q1 results reported in March, showing a 74 percent uptick in gross margins on the strength of a 76 percent increase in operating income from the company’s cosmeceutical and biomedical commercialization. Income growth to $1.62 million in revenue was led by a 5 percent sales jump at the company’s Lifeline Skin Care subsidiary, which specializes in providing rejuvenating skin care products based on nanosphere-enscapsulated proteins extracted from parthenogenetic stem cells. Additionally, the company made waves in the regenerative therapy industry with a talk given in May at the International Society for Cellular Therapy’s (ISCT) annual meeting by the company’s CSO, Ruslan Semechkin, Ph.D., highlighting the potential of hpNSCs for treating PD. The ISCT is the leading global association focused on innovative preclinical and translational cell therapy product development, and Dr. Semechkin’s talk on hpNSC therapy left a lasting impression on key industry participants who attended the Regeneration and Nervous System Repair session at the organization’s 21st annual meeting in Las Vegas.

This move to reverse split the common stock and up-list to a major exchange comes at an auspicious time for International Stem Cell Corporation as the company rockets towards commercialization of a potentially genuine treatment option for PD sufferers and their families. With GlobalData estimates on the PD treatment market running into the $5.3 billion range within the next seven years alone, growing at a compound annual rate of over four percent, International Stem Cell Corporation is poised to become one of the big names in PD treatment, especially considering the company’s ample IP position. The company has made a herculean effort thus far to globally secure its core technology, as well as specific pluripotent human parthenogenetic stem cell (hpSC) lines, with 16 issued patents and 91 pending applications spanning 15 patent families, as well as eight more pending applications across four other patent families related specifically to skin care products. International Stem Cell Corporation has even licensed an additional portfolio of 11 issued and 14 pending patents/applications covering eight patent families in order to further secure its broad-spectrum and rapidly developing hpSC treatment pipeline.

This pipeline includes developing the same hpNSCs used to treat PD, in order to provide stroke patients with the first real solution to this leading cause of adult disability, and the company already has robust preclinical evidence that injection of these highly-pure hpNSCs can be used to actually reverse functional deficits when applied even several weeks after the initial event. This one development would be a major commercial victory for the company and it would also largely establish the concrete viability of its parthenogenetic technology for creating commercial-scale, implant-ready cell banks for the ischemic (roughly 87 percent of cases) stroke treatment and other markets. Not to mention being a game-changer for the roughly 691,650 people every year in the U.S. who suffer from ischemic strokes. People whose only current option is costly, laborious, logistically difficult to implement, and often ineffective cognitive/functional rehabilitation. Commercial success in either PD or ischemic stroke would roundly validate the company’s underlying therapeutic approach for treating other diseases and disorders as well, potentially opening a floodgate for the company and allowing them the kind of financial muscle and industry clout needed to knock down additional targets with hpSC-based therapies.

The company’s hpSC technology is currently being developed for areas such as age-related macular degeneration via parthenogenetically-derived human retinal epithelium (RPE) cell therapy, as well as for corneal blindness and many other eye diseases/disorders via the production of corneal cells and whole corneal tissue. This same technology also shows great promise for treating metabolic (and other types of) liver diseases, such as Crigler-Najjar syndrome (inherited), and the company has already successfully created and characterized stem cell-derived liver cells under its CytoHep program, whose transplantation has been shown to effectively delimit the brain and nerve damage associated with Crigler-Najjar syndrome in preclinical animal models.

If one observes all of these emerging hpSC treatment vectors from a wide angle, it becomes strikingly apparent that we could potentially be treating a whole host of degenerative and other diseases/disorders with 100 percent ethically derived stem cell technology. International Stem Cell Corporation is at the forefront of this industry and the shoring-up of its share structure in anticipation of up-listing to a major exchange, in conjunction with the upcoming landmark clinical trials in PD, for which the company has already comfortably sustained the cost on and manufactured a cell bank of over 2.6 billion high-purity hpNSCs (enough to satisfy all foreseeable clinical trial needs), is an extremely bullish indicator to the investment community about where the company is heading.

Continued success of the company’s already commercialized cosmeceutical and biomedical product operations forms a key backdrop for International Stem Cell Corporation when it comes to funding ongoing clinical and preclinical efforts, further differentiating the company (alongside its strong IP position) from competitors.

Take a closer look by visiting www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered